Ralinepag vs Treprostinil (Orenitram)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Ralinepag

Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.

Phase 3 in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT03626688 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).

Next expected readout: December 2026 · NCT03683186 (registry estimate)

Reported efficacy

Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)

Result source: NCT03626688

Treprostinil (Orenitram)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT00325403 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 349 participants enrolled and 228 included in the prespecified primary analysis. The clinical primary endpoint was met: oral treprostinil produced a statistically significant placebo-corrected improvement in six-minute walk distance at Week 12.

Reported efficacy

Six Minute Walk Distance (6MWD) (Baseline and Week 12): Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) (met)

Result source: NCT00325403

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Ralinepag: 7 of 7 rows · Treprostinil (Orenitram): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRalinepag
Rows use multiple source trials
Treprostinil (Orenitram)
Rows use multiple source trials
6MWD - Change
absolute change · m
36.2 vs 29.4 placebo m @ 22wka,b,c,d
NCT02279160 · Phase 2 · registry result, not featured evidence
395.4 vs 372.3 placebo m @ 24wka,b,c,d
NCT01560624 · Phase 3 · registry result, not featured evidence
6MWD - Change
absolute change · m
No placebo or comparator arm
-120 m @ 221wkb,e
NCT02279745 · Phase 2 · registry result, not featured evidence
2.7 m @ 24wkf,b,e
NCT02276872 · Phase 2 · registry result, not featured evidence
show 2 more doses
22.1 m @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence
12.8 m @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Cardiac Index Change L/Min M2
absolute change · L/min
No placebo or comparator arm
0 L/minb,g
NCT02279745 · Phase 2 · registry result, not featured evidence
0.303 L/min @ 24wkf,b,g
NCT02276872 · Phase 2 · registry result, not featured evidence
show 2 more doses
0.767 L/min @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence
0.121 L/min @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
44.4%h
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
15%
NCT02279160 · Phase 2 · registry result, not featured evidence
21.9%i
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
42.1%
NCT01560637 · Phase 3 · registry result, not featured evidence
76.7%
NCT01027949 · Phase 3 · registry result, not featured evidence
57.2%
NCT01560624 · Phase 3 · registry result, not featured evidence
12.1%
NCT00325442 · Phase 3 · registry result, not featured evidence
10%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
15.6%h
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
—
NCT02279160 · Phase 2 · registry result, not featured evidence
—i
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
13.4%
NCT01560637 · Phase 3 · registry result, not featured evidence
19.2%
NCT01027949 · Phase 3 · registry result, not featured evidence
—
NCT01560624 · Phase 3 · registry result, not featured evidence
—
NCT00325442 · Phase 3 · registry result, not featured evidence
10%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
46.7%h
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
10%
NCT02279160 · Phase 2 · registry result, not featured evidence
17.9%i
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
43.8%
NCT01560637 · Phase 3 · registry result, not featured evidence
61.2%
NCT01027949 · Phase 3 · registry result, not featured evidence
33.5%
NCT01560624 · Phase 3 · registry result, not featured evidence
18.4%
NCT00325442 · Phase 3 · registry result, not featured evidence
50%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
33.3%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
h
headache 64.4%
diarrhoea 37.8%
pain in jaw 33.3%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
headache 77.5% (placebo 28.6%)
nausea 50% (placebo 23.8%)
diarrhoea 47.5% (placebo 14.3%)
NCT02279160 · Phase 2 · registry result, not featured evidence
i
headache 62.9% (placebo 19.5%)
diarrhea 30.5% (placebo 15.6%)
nausea 29.8% (placebo 18.2%)
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
headache 69.8%
diarrhoea 66.2%
flushing 42.8%
NCT01560637 · Phase 3 · registry result, not featured evidence
headache 78.1%
diarrhoea 66.2%
nausea 56.5%
NCT01027949 · Phase 3 · registry result, not featured evidence
headache 74.9% (placebo 34.9%)
diarrhoea 69.4% (placebo 28.5%)
flushing 44.5% (placebo 7.8%)
NCT01560624 · Phase 3 · registry result, not featured evidence
headache 86.2% (placebo 36.9%)
nausea 64.4% (placebo 34.1%)
diarrhea 60.9% (placebo 27.3%)
NCT00325442 · Phase 3 · registry result, not featured evidence
vomiting 90%
nausea 70%
diarrhoea 60%
NCT02276872 · Phase 2 · registry result, not featured evidence
headache 80%
diarrhoea 70%
cough 50%
NCT02276872 · Phase 2 · registry result, not featured evidence
headache 100%
diarrhoea 75%
nausea 75%
NCT02276872 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 22 weeks versus 24 weeks.
  5. eAssessment timepoints differ: 221 weeks versus 24 weeks.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gThe assessment timepoint is not available for both results.
  8. hPopulation comparability has not been reviewed for these studies.
  9. iPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ralinepag

PVR Change Dyn S Cm5 -52.2 seconds
absolute change · seconds
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Time to First Clinical Worsening Event 13.04 months
time to event · months
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence · converted to months from 56.5 weeks as posted
6MWD - Change 37 m
absolute change · m
No placebo or comparator arm
End of Study (Time of Discontinuation of Study by Sponsor)
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Output 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Pulmonary Arterial Pressure -2 mmHg
absolute change · mmHg
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
PVR 514.6 vs 512 placebo cm @ 22wk
absolute change · cm
NCT02279160 · Phase 2 · registry result, not featured evidence

Treprostinil (Orenitram)

6MWD - Change 25 vs -5 placebo m @ 12wk
absolute change · m
Change in 6MWD from Baseline to Week 12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
16.5 vs 5.8 placebo m @ 12wk
Change in 6MWD from Baseline to Week 12
NCT00325442 · Phase 3 · registry result, not featured evidence
6MWD - Change 8 vs 0 placebo m @ 11wk
absolute change · m
Change in 6MWD from Baseline to Week 11
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
6MWD - Change 17 vs 0 placebo m @ 8wk
absolute change · m
Change in 6MWD from Baseline to Week 8
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
15 vs 7 placebo m @ 8wk
Change in 6MWD from Baseline to Week 8
NCT00325442 · Phase 3 · registry result, not featured evidence
6MWD - Change 7 vs 0 placebo m @ 4wk
absolute change · m
Change in 6MWD from Baseline to Week 4
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
5.5 vs 2.1 placebo m @ 4wk
Change in 6MWD from Baseline to Week 4
NCT00325442 · Phase 3 · registry result, not featured evidence
Clinical Worsening 9.9% (n=151) vs 10.4% (n=77) placebo @ 12wk
event count · % of participants
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 · converted to % from 15 participants as posted
show 1 more result
4.6% (n=174) vs 6.8% (n=176) placebo @ 16wk*
NCT00325442 · Phase 3 · registry result, not featured evidence · converted to % from 8 participants as posted
Borg Dyspnea 0 vs 0 placebo score @ 12wk
absolute change · score
Change in Borg dyspnea score from Baseline to Wk12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
Dyspnea-Fatigue Index -0.3 vs -0.3 placebo score @ 12wk
absolute change · score
Change in dyspnea-fatigue index from BL to Wk 12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
Six Minute Walk Change 20.1 m @ 48wk
absolute change · m
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
Borg Dyspnea -0.49 score @ 48wk
absolute change · score
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
show 3 more results
-1.56 score @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence
0.05 score @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence
-0.83 score @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
WHO Functional Class -0.2 score @ 48wk
absolute change · score
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
NT-proBNP -179.23 pg/mL @ 48wk
absolute change · pg/mL
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
6MWD - Change 22 m @ 48wk
absolute change · m
Extension (open-label)
No placebo or comparator arm
NCT01027949 · Phase 3 · registry result, not featured evidence

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Orenitram)'s landscape